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doi:10.1016/j.jtcvs.2008.02.001Objective: The risk factors associated with death after thoracic endovascular aortic
repair are poorly understood. The aim of this study is to analyze the risk factors asso-
ciated with early and late mortality after thoracic endovascular aortic repair.
Methods: A total of 153 patients underwent 184 thoracic endovascular aortic repairs
between 1998 and 2005. Prospectively collected data were entered into statistical soft-
ware. Univariate and multivariate analyses were performed.
Results: The underlying pathologies included descending thoracic aortic aneurysm
(n 5 91), acute type B aortic dissection (n 5 25), chronic type B aortic dissection
(n5 42), aortic transection (n5 12), and penetrating aortic ulcer (n5 14). Thoracic
endovascular aortic repair was technically successful in all but 3 patients. Another 3
patients required an open repair within the first month. Early and late mortality rates
were 9.8% (n 5 18) and 19% (n 5 35) in a 16-month average period of follow-up,
respectively. Type I procedural endoleak was the only significant predictor of early
death in the multivariate model (P5 .0036; odds ratio: 8.4; 95% confidence interval:
1.6–43.9). Multivariate Cox regression revealed chronic obstructive pulmonary dis-
ease (P 5 .024; odds ratio: 3.8; 95% confidence interval: 1.2–12.1), postoperative
myocardial infarction (P 5 .0053; odds ratio: 9.7; 95% confidence interval: 2.0–
48.4), and acute renal failure (P 5 .0006; odds ratio: 22.8; 95% confidence interval:
3.8–137.6) to be independent risk factors for late mortality.
Conclusion: Procedural type I endoleak is an independent risk factor of early mortality
after thoracic endovascular aortic repair. Chronic obstructive pulmonary disease,
postoperative myocardial infarction, and acute renal failure are predictors of late death
in the multivariate analysis.
T
horacic endovascular aortic repair (TEVAR) is an emerging option to open
repair in a selected population with aortic pathologies. Proposed advantages
of TEVAR include shorter operative time, less blood loss, decreased need
for general anesthesia, and shorter hospital stays.1-3 TEVAR avoids morbid thoracot-
omy and thoracoabdominal incisions, cardiopulmonary bypass, aortic crossclamping,
and hypothermic circulatory arrest. A recent US multicenter trial with the Gore TAG
thoracic endoprosthesis (WL Gore and Associates, Flagstaff, Ariz) involved patients
with an underlying aneurysm who met anatomic eligibility criteria and were candi-
dates for open surgical repair.4 The results of this study were encouraging and dem-
onstrated feasibility and durability while reducing morbidity and mortality in early
postoperative follow-up.4
The TAG trial, however, did not review and analyze the variables associated with
death after TEVAR. To our knowledge, there are no published series on TEVAR that
have focused on the risk factors of early versus late mortality. The aim of this study
was to review our experience with TEVAR and to identify the risk factors of early and
late mortality after TEVAR.The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 5 1103
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CT 5 computed tomography
POD 5 postoperative day
TEVAR 5 thoracic endovascular aortic repair
Patients and Methods
A total of 153 consecutive patients were referred to Harbor-
UCLA Medical Center for TEVAR between October of 1998 and
September of 2005. A total of 184 procedures were performed on
117 male patients (76.5%) and 67 female patients. After approval
was obtained from the institutional review board, the patients
were offered TEVAR through a single institution investigator In-
vestigational Device Exemption approved by the Food and Drug
Administration. All patients signed consent forms for the use of
these investigational devices and agreed to participate in the surveil-
lance protocols after deployment of the devices.
Inclusion and Exclusion Criteria
The inclusion criteria for TEVAR included all symptomatic aneu-
rysms of the descending thoracic aorta, asymptomatic fusiform aneu-
rysms of the descending thoracic aorta with at least twice the size or
proximal normal aorta, saccular aneurysm greater than 5 cm, compli-
cated acute Stanford type B aortic dissections, aneurysmal degenera-
tion (with adiameter at least twice the size or proximal normal aorta) of
(or complicated) chronicStanford typeB aortic dissections, symptom-
atic penetrating aortic ulcers, and traumatic aortic transections. The
term ‘‘complicated dissection’’ was defined as persistent/unrelenting
back pain despite maximal medical therapy, uncontrollable hyperten-
sion, aortic enlargement more than 5 mm per year, malperfusion
syndromes, or (imminent) rupture. Other inclusion criteria were sign-
ing the informed consent and agreeing to follow-up in the institutional
surveillance program. Furthermore, the patient’s arterial anatomy
must have met device-specific requirements to be a candidate for
TEVAR. Adequate proximal and distal landing zone and well-sized
access vessels were evaluated before offering TEVAR to the patients.
The exclusion criteria included Stanford type A (or retro-A) aor-
tic dissections, aneurysmal pathologies of ascending thoracic aorta,
arterial anatomy unsuitable for TEVAR, patients with connective
tissue disorder, age less than 18 years, pregnancy, systemic infec-
tion, and hypercoagulable disorder.
Definition of Endoleaks
Endoleaks were reported as defined as reporting standard byChaikof
and coworkers.5 Type I endoleaks are leaks from the proximal (Ia) or
distal (Ib) landing zone. Type II endoleaks are not connected or asso-
ciated to the landing zones or the junction between various stent
grafts. Type III endoleaks are leaks between the junctions of 2 or
more stent grafts. Type IV endoleaks are caused by graft wall poros-
ity and are a problem with first-generation stent materials. Type V
endoleak (endotension) is an increase in aneurysm diameter or pres-
sure in the excluded sac without radiologic evidence of endoleak.
Statistical Analysis
Patient data, including demographics, risk factors, clinical symp-
toms, procedural details, computed tomography (CT) scans, angio-1104 The Journal of Thoracic and Cardiovascular Surgery c Mgrams, postoperative complications, secondary interventions, and
mortality, were collected in a retrospective manner by chart review
and by review of prospective and concurrent Food and Drug Admin-
istration reports of the respective Investigational Device Exemption
protocols. All data were entered into an electronic database. Statis-
tical analysis was performed using the SPSS 13.0 for Windows sta-
tistical software package (SPSS Inc, Chicago, Ill). Fisher exact test
and Cox regression were performed for univariate analysis of risk
factors for early (within the first 30 days) and late mortality after
TEVAR. Variables with P values less than .05 in the univariate anal-
ysis were included in the stepwise model selection procedure of
multivariate analysis. Multivariate logistic regression and Cox
regression were used to evaluate the effects of a set of perioperative
outcome variables on early and late death, and to establish indepen-
dent risk factors. The actuarial survival was computed according to
the Kaplan–Meier log-rank method. The statistical analysis under-
went a mathematical review by a biostatistician from the University
of Nebraska Medical Center.
The follow-up physical examination, contract CT, and labora-
tory work were performed according to the institutional surveillance
protocol at 1, 6, and 12 months and yearly thereafter for 5 years. The
protocol for postoperative imaging includes a 3-phase multidetector
CT angiogram. A noncontrast scan through the chest and abdomen
is followed by contrast computed tomographic angiography using
100 mL of nonionic contract. A 2-minute delayed CT scan is
performed to enhance detection rate for endoleaks.
Results
A total of 153 consecutive patients (94 male, 59 female)
underwent 184 endovascular procedures. This included
primary and subsequent endovascular interventions. A total
of 145 patients underwent endovascular repair using the
Talent device (Medtronic, Minneapolis, Minn). Another
37 patients were treated with the Thoracic AneuRx graft
(Medtronic), and an Excluder or TAG device (Gore, Flag-
staff, Ariz) was deployed in the remaining 2 patients. The
underlying pathology was descending or transverse aortic
aneurysm in 91 patients (49%), acute type B dissection in
25 patients (14%), and chronic type B dissection in 42 pa-
tients (23%). Twelve patients (7%) had traumatic aortic
transection, and 14 patients (8%) were treated for penetrat-
ing aortic ulcer.
The majority of the patients were transferred from out-
side facilities. They were evaluated by cardiothoracic or
vascular surgeons and deemed to be poor or nonoperative
candidates. Some 35 of 153 patients (19%) underwent emer-
gency TEVAR for ruptured/leaking aorta, and 75 patients
(41%) had a previous major cardiac or aortic operation.
Table 1 shows a selected list of the preoperative character-
istics and comorbidities of this patient cohort. Figure 1 is
the schematic representation of the distribution of proximal
landing zones. Aortic pathologies involving the proximal or
distal descending thoracic aorta were present in 127 and 51
patients, respectively. Four patients had aneurysms of the
aortic arch, and 2 patients had type II thoracoabdominal
aortic aneurysms.ay 2008
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TEVAR was technically successful in 98% of the patients. In
3 patients, TEVARwas not achieved. The first patient, an 85-
year-old woman with aortic transection who was transferred
via helicopter from another city, had aortic rupture in the
endovascular suite before treatment. The second patient, an
85-year-old woman with a thoracic aneurysm, died of myo-
cardial infarction on the operating table. The third patient,
a 76-year-old woman with a 7-cm aneurysm of the descend-
ing thoracic aorta, had marginal access vessels. She was not
a surgical candidate. Given her intraoperative access issues,
the endovascular procedure was aborted without any harm
to the patient.
Three other patients required open repair after undergoing
TEVAR. All 3 patients underwent operation within the first
month of TEVAR. All 3 patients survived the TEVAR/
open repair without any significant sequelae in the follow-
up period. A 43-year-old man with multiple intra-abdominal
and pelvic injuries had a transected aorta. The patient devel-
oped a localized dissection of the proximal landing zone with
significant type I endoleak. He underwent immediate open
graft replacement of the proximal descending thoracic aorta.
He developed postoperative acute renal failure and respira-
tory failure but was discharged in satisfactory condition on
postoperative day (POD) 39. A 66-year-old woman with
lupus aortitis and a ruptured aneurysm of the mid-descending
thoracic aorta underwent exclusion with a stent graft. Three
weeks later, she required a reintervention for a newly diag-
nosed localized dissection at the proximal landing zone. A
month after the first TEVAR procedure, she underwent the
Bentall operation with total arch replacement for a retrograde
dissection that was diagnosed in a follow-up CT scan. She
TABLE 1. Demographics of patients treated by thoracic
endovascular aortic repair
Characteristics All patients (n 5 184)
Age (median): range 18–92 y 71 6 13.7
s/p cardiac surgery 18 (10%)
s/p aortic surgery 70 (38%)
Ascending aortic 5 (3%)
Aortic arch 8 (4%)
Descending aorta 23 (13%)
Abdominal aorta 34 (18%)
Preoperative creatinine (mg/dL) 1.5 6 1.7
Coronary artery disease 49 (26%)
Preoperative myocardial infarction 4 (2%)
Congestive heart failure 16 (7%)
Chronic obstructive pulmonary disease 32 (17%)
Peripheral vascular disease 25 (14%)
Preoperative stroke 17 (9%)
Diabetes mellitus 17 (9%)
Hypertension 112 (61%)
Obesity (body mass index $ 30 kg/m2) 8 (4%)The Journal of Thortolerated the procedure well and was discharged 10 days
later. A 58-year-old woman with an aneurysmal degeneration
of the chronic Stanford type B aortic dissection had a retro-
grade dissection into the ascending aorta requiring immediate
ascending aortic replacement.
Neurologic Deficits
Postoperative paraplegia or paraparesis developed in 8 pa-
tients (4.3%). Two patients recovered completely. Postoper-
ative stroke developed in 8 other patients (4.3%) with
aneurysmal pathology. Two patients recovered completely.
There was no correlation between the coverage of left subcla-
vian artery and the incidence of posterior stroke. The analysis
of risk factors associated with postoperative spinal cord
injury and stroke has been discussed.6 The incidence of post-
operative spinal cord injury, stroke, and 30-day mortality is
summarized in Table 2.
Figure 1. Proximal landing zones for all patients undergoing tho-
racic endovascular repair. Zone 0: covering the innominate artery.
Zone 1: covering the left carotid artery. Zone 2: covering the left
subclavian artery. Zone 3: involving proximal 1/3 of the descending
thoracic aorta. Zone 4: involving distal 2/3 of the descending
thoracic aorta.acic and Cardiovascular Surgery c Volume 135, Number 5 1105
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Early mortality was 9.8% (18/184) in the entire cohort, and
this was similar for patients with various aortic pathologies
(Table 2). The causes of early death were myocardial infarc-
tion in 7 patients, retrograde dissection/cardiac tamponade in
3 patients (on PODs 2, 3, and 8), sepsis/pneumonia in 3
patients, ruptured aorta in 2 patients (1 patient with traumatic
transection before TEVAR and 1 patient with ruptured Kom-
merell diverticulum on POD 14 after carotid to bilateral sub-
clavian bypass and zone 2 TEVAR), stroke in 1 patient (on
POD 7), aortoesophageal fistula in 1 patient (on POD 5 after
reintervention for TEVAR 5 months after initial TEVAR
for aortoesophageal fistula), and aortobronchial fistula in 1
patient (recurrent hemorrhage on POD 9 after TEVAR).
The causes of late mortality (n 5 19) were unknown in 6
patients (2, 6, 31, 46, 47, and 61 months after TEVAR), myo-
cardial infarction in 5 patients (2, 2, 4, 8, and 22 months after
TEVAR), pneumonia in 4 patients (3, 3, 22, and 24 months
after TEVAR), and cancer in 4 patients (3, 6, 6, and 13
months after TEVAR).
A univariate analysis perioperative variable was under-
taken to determine the risk factors associated with early mor-
tality (Table E1). The following variables were associated
with early mortality: peripheral vascular disease, postopera-
tive bleeding and transfusion, intraoperative hypotension,
need for general anesthesia, procedural type I endoleak, post-
operative myocardial infarction, vascular injury, and inten-
sive care unit stay 2 days or more. The remainder of the
other variables that were reviewed did not reveal any statisti-
cal significance. Multivariate logistic regression was used
to calculate independent risk factors of early death after
TEVAR. Procedural type I endoleak was the only significant
predictor of early death in themultivariate model (P5 .0036).
The patients with procedural endoleak are 8.4 times as likely
to have early death as those without procedure endoleak (odds
ratio 5 8.4, 95% confidence interval: 1.6–43.9).
The overall 1- and 5-year survivals according to Kaplan–
Meier were 80% and 67%, respectively (Figure 2). Aortic-
related survival was 90% at 5 years (Figure 2). This was
TABLE 2. Outcome of patients undergoing thoracic
endovascular aortic repair based on underlying pathology
Aortic pathology SCI (%) Stroke (%)
Early
mortality
Aortic aneurysm (n 5 91) 8 (8.8%) 5 (5.5%) 9 (9.9%)
Acute type B aortic
dissection (n 5 25)
0 1 (4%) 2 (8%)
Chronic type B dissection
(n 5 42)
0 2 (4.8%) 5 (11.9%)
Aortic transection (n 5 12) 0 0 1 (8.3%)
Penetrating ulcer (n 5 14) 0 0 1 (7.1%)
Total (n 5 184) 8 (4.3%) 8 (4.3%) 18 (9.8%)
SCI, Spinal cord injury.1106 The Journal of Thoracic and Cardiovascular Surgery c Mdefined as all mortalities associated with aortic rupture and
early mortality associated with the TEVAR procedure.
Table E2 contains the univariate analysis of variables
associated with late mortality. The following risk factors of
late mortality were identified: peripheral vascular disease,
coronary artery disease, congestive heart failure, chronic
obstructive pulmonary disease, postoperative myocardial
infarction and acute renal failure, vascular injury, procedural
blood loss of 400 mL or more, and intensive care unit stay of
2 days or more. Cox regression analysis revealed chronic
obstructive pulmonary disease, postoperative myocardial in-
farction, and acute renal failure to be independent risk factors
of mortality (Table 3).
Endoleaks
Procedural endoleaks were detected in 4.9% (9/184) of
TEVARs. All were type I endoleaks. Three patients (3/9)
had resolution of the endoleak in follow-up CT scans. One
patient with traumatic transection required conversion to
open repair (discussed previously). Three patients died of
retrograde dissection/cardiac tamponade, stroke, and ruptured
Kommerell’s aneurysm on PODs 7, 8, and 14, respectively
(discussed previously). Two patients (2/9) underwent reinter-
ventions at 38months and 66months. One had successful res-
olution of the endoleak by endovascular approach. However,
an 87-year-oldwomanwith large chronic typeB aortic dissec-
tion continues to have a small type Ia endoleak. She is not
a candidate for open surgical repair to treat her endoleak.
The median follow-up was 16 6 17 months (range 1–72
months) and was complete for 92% of the patients undergo-
ing TEVAR. During this period of time, 36 late endoleaks
Figure 2. Kaplan–Meier survival curve comparing aortic-related
(solid line) and overall mortality (gray line). At least 1 censored
patient (tick marks) because of the length of the follow-up.ay 2008
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type I endoleaks, 5.6% (2/36) were type II endoleaks, 11.1%
(4/36) were type III endoleaks, and 2.8% (1/36) were type V
endoleak. Twenty-three patients (15%) required 34 of 184
(18.5%) reinterventions in the follow-up (including the afore-
mentioned 2 procedural endoleaks). Fifteen patients required
only 1 reintervention, 5 patients required 2 reinterventions,
and 3 patients required 3 reinterventions. No additional
open operation was performed to treat endoleak beyond the
first month.
Discussion
The prevalence of descending thoracic aortic aneurysm is
estimated to be 10 in 10,000 elderly adults, with approxi-
mately 40% of these aneurysms confined to the thoracic
aorta.7 Open repair of the descending and thoracoabdominal
aortic and other aortic pathologies remains the gold stan-
dard.8-12 Endovascular repair is an emerging alternative to
the open repair in a selected patient population. The patients
in the current study had informed consent and were offered
TEVAR for off-label indications through a single institution
investigator Investigational Device Exemption approved by
the Food and Drug Administration. The majority of these pa-
tients were not open surgical candidates, and TEVARwas the
only possible treatment option.
The early survival of the patients undergoing TEVAR in
this study is equal to the most historical groups undergoing
open repair.8-12 The early mortality in the TAG study was
2.1% in the TEVAR group compared with 11.7% for the
open repair control group for isolated ‘‘low-risk’’ descending
thoracic aorta.13 All acute aortic syndromes with worse prog-
nosis were excluded, and all included patients were deemed
good surgical candidates assessed by 17 centers of excel-
lence. The outcome of this series represents arguably the
best assessment available of comparative real-world results
for open repair of the descending thoracic aorta. Another
comparative series of TEVAR versus the open repair comes
from a study from the Massachusetts General Hospital.14 A
TABLE 3. Multivariate predictors of overall survival (Cox
regression)
Hazard ratio 95% CI P value
Chronic obstructive pulmonary
disease
No 1 — .024
Yes 3.8 1.2–12.1
Postoperative myocardial infarction
No 1 — .0053
Yes 9.7 2.0–48.4
Acute renal failure
No 1 — .0006
Yes 22.8 3.8–137.6
CI, Confidence interval.The Journal of Thortotal of 81 patients undergoing TEVAR were compared
with 91 concurrent patients with open repair for the descend-
ing thoracic aorta or thoracoabdominal aortic aneurysm. All
emergency/ruptured cases were excluded from the analysis.
Early mortality was 8.9% versus 13.1% for the TEVAR
and open control groups, respectively.
The long-term survival of patients undergoing TEVAR
compared with open repair has been evaluated by few investi-
gators. At the 54-month average follow-up, the actuarial sur-
vival was similar between the 2 groups in the trial from
MassachusettsGeneralHospital.14 Similar findingswere found
by the TAG investigators, showing a 2-year survival of 78%
and 76% for the TEVAR and open control groups, respec-
tively.13 TEVAR seems to have no significant effect on the
long-term survival of patientswhen comparedwith patients un-
dergoing open repair. The 5-year survival was 67%. This sug-
gests that the long-term survival in the TEVAR group is not
better than in the open repair group, despite a lower early mor-
tality in the TEVAR group. Czerny and coworkers15 observed
a 65% to 69% 5-year survival in patients undergoing TEVAR
with an underlying aneurysm (excluding acute aortic syn-
dromes), which is consistent with the results of current study.
TEVAR may reduce early mortality in this multimorbid
patient population, but in the long-term follow-up, the
patients will die of comorbidities such as cancer, coronary
artery disease, chronic renal failure, and chronic obstructive
pulmonary disease. The latter 3 variables were all indepen-
dent risk factors of long-term mortality in the current study.
Renal failure and chronic lung disease have been implicated
with poor long-term outcome in patients undergoing open
repair of the thoracic aortic pathologies.16 The association
of coronary artery disease and cancer with poor long-term
outcome needs no further discussion, because they represent
the top 2 ‘‘killers’’ in the western countries.
Type I endoleak was the only independent risk factor for
early mortality in this study. Careful intraoperative evalua-
tion for endoleaks (intravascular ultrasound and multiplane
‘‘completion aortogram’’) is crucial to detect procedural en-
doleaks, because many are subtle and may be missed by
just a regular aortogram. Given the prognostic significance
of a procedural endoleak, it needs to be addressed aggres-
sively in the endovascular suite. In many cases, there are en-
dovascular options to treat type I endoleak.17 However, open
conversion and repair should be offered to patients who have
exhausted endovascular options. Furthermore, open surgical
repair should be strongly considered in patients who are at
significant risk for procedural type I endoleak. This rein-
forces the importance of comprehensive preoperative evalu-
ation of the patients with aortic pathologies by an
experienced group of physicians. These patients should be
discussed in multidisciplinary clinics before offering them
open or endovascular repair.
The endoleak rate in current study was 4.9% (9/184) in the
first month and 43 (23.4%) during the entire follow-upacic and Cardiovascular Surgery c Volume 135, Number 5 1107
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the patients undergoing reintervention during the follow-
up. Twenty-three patients (15%) required reinterventions
for ongoing type I or III endoleak, or type II/V endoleak
with sac expansion. This endovascular strategy has been
the mainstay of treatment of endoleaks after TE-
VAR.2,3,4,18-20 The rate of endoleak in the TAG trial was
lower at 11% (12/110) and 9% (7/80).13 This is probably
due to a selection bias. The TAG trial included a relatively
healthy patient cohort with aneurysmal pathology who
were open surgical candidates. In comparison, the endoleak
rate was 29% in the other large studies by Czerny and col-
leagues15 and Parmer and colleagues.17 As in these series,
the late endoleaks in this study were managed successfully
in a nonsurgical fashion.
Because the procedural endoleak has a significant impact
on the outcome, it is important to discuss the variables asso-
ciated with procedural endoleak. Most important variables
contributing to type I endoleak are modifiable. The most
important risk factor for a procedural type I endoleak is an
inadequate proximal or distal landing zone.15 Significant cal-
cification or thrombus at the proximal/distal landing zone
may impede complete apposition of the stent graft to the land-
ing zone, thereby contributing to a type I endoleak. There-
fore, patients with inadequate or poor quality proximal or
distal landing zones need to be evaluated for surgical repair,
if they are thought to be operative candidates. Endovascular
repair should be offered to these patients with prohibitive
operative risk if conservative management is not a reasonable
option, and only after a detailed informed consent is obtained.
Furthermore, improper stent graft selection can contribute
to procedural endoleak. Poor preoperative/intraoperative im-
aging and sizing of the proximal and distal landing zone can
lead to under- or oversizing of the stent graft, both of which
can contribute to endoleak. All these points underscore the
importance of preoperative planning and experience in endo-
vascular procedures. Surgeons should have at least 6 months
of dedicated training before performing these procedures.
The length of the treated aorta and the number of stent
grafts are also associated with an increased rate of endo-
leak.15,17 Type III endoleak is more common when the over-
lap between themultiple stent grafts is marginal. Other factors
associated with procedural endoleak include the male gender
and larger aneurysm size.17
There are several limitations to the current study. It repre-
sents a retrospective analysis of prospectively collected data
as part of an investigational protocol. There is a lack of
a risk-adjusted control group undergoingopen repair for similar
aortic pathologies. Furthermore, the follow-up is less than
100% complete, and the cause of death in 6 patients is undeter-
mined in the follow-up. One may raise the argument that the
causeofdeath in those 6 patientswas related to the treated aortic
pathology. Because the majority of these patients were trans-
ferred from other hospitals and cities, our efforts did not suc-1108 The Journal of Thoracic and Cardiovascular Surgery c Mceed in tracking the patients who were lost to follow-up. A
larger trial using a multicenter registry is recommended to sub-
stantiate theprognostic findings in this study and to establish the
long-term ($10 years) durability and safety of the stent grafts.
Conclusions
This series demonstrates that type I procedural endoleak is
the only significant predictor of early death in patients under-
going TEVAR. Superior imaging and careful preoperative
planning may reduce the procedural endoleak. Multivariate
analysis revealed chronic obstructive pulmonary disease,
postoperative myocardial infarction, and acute renal failure
to be independent risk factors for late death after TEVAR.
All patients should be followed up closely to identify endo-
leaks and to establish the durability of stent grafts.
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CDTABLE E1. Univariate predictors of early mortality (Fisher
exact test)







,60 37 4 1.0
$60 96 12
Gender
Male 84 10 1.0
Female 50 6
ICU stay (d)
0–1 37 1 .039
$2 41 9
Hospital stay (d)
0–5 41 3 .51
$6 50 7
Pathology
Aneurysm 65 8 .97
Acute dissection 21 2
Chronic dissection 24 4
Transection 11 1
Penetrating ulcer 13 1
Rupture/leaking
No 105 13 1.0
Yes 29 3
Coronary artery disease
No 84 9 .38
Yes 34 6
Hypertension
No 34 4 1.0
Yes 86 11
Diabetes mellitus




No 106 12 .37
Yes 3 1
Congestive heart failure
No 101 10 .14
Yes 10 3
On hemodialysis
No 105 11 1.0
Yes 1 0
Peripheral vascular disease
No 93 7 .019
Yes 13 5
Preoperative stroke
No 96 10 1.0
Yes 11 1
Obesity
No 73 10 1.0
Yes 7 0
Smoking
No 41 3 .25
Yes 62 11
TABLE E1. Continued








No 85 6 .068
Yes 23 6
Operating time (min)
,180 48 3 .30
$180 41 6
Procedural urine output
,500 52 4 .34
$500 42 7
Blood loss (mL)
,400 50 3 .22
$400 58 9
Contrast use (mL)
,100 38 2 .44
$100 42 5
Fluoroscopy time (min)
,8 46 3 .17
$8 32 6
Neck diameter (mm)
,31 45 3 .52
$31 62 7
Neck length (mm)
,30 37 4 .41
$30 44 2
General anesthesia
No 72 5 .044
Yes 39 9
Intraoperative hypotension
No 61 4 .025
Yes 5 3
Use of adenosine for cardiac arrest
No 58 7 .72
Yes 26 2
Cerebrospinal fluid drain
No 74 8 1.0
Yes 7 0
Iliac artery conduit
No 104 12 .74
Yes 26 4
Brachial/radial access
None 69 7 .65
Brachial artery 15 1
Radial artery 21 4
No. of stent grafts




No 74 6 .11
Yes 27 6
Landing zone
0–2 32 7 .13
3–4 102 91109.e1 The Journal of Thoracic and Cardiovascular Surgery c May 2008
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CDTABLE E1. Continued






Internal iliac artery coverage
No 79 8 1.0
Yes 5 0
Procedural endoleak
None 84 6 .024
Type 1 5 3
Endoleak in follow-up





No 78 8 .001
Yes 3 5
Packed red blood units
0 60 3 .0098
$1 17 6
Postoperative bleeding
No 78 9 .015
Yes 2 3
Infection
No 70 9 .65
Yes 11 2
Vascular injury
No 77 7 .0063
Yes 4 4
Distal embolization
No 78 10 .40
Yes 3 1
Vascular thrombosis
No 79 10 .12
Yes 0 1
Acute renal failure
No 76 9 .064
Yes 5 3
Stent graft kink
No 80 11 1.0
Yes 1 0
ICU, Intensive care unit.The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 5 1109.e2
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CDTABLE E2. Univariate predictors of overall survival (Cox
regression)
Hazard ratio 95% CI P value
Age (y)
,60 1 – .23
$60 1.9 0.7–5.5
Gender
Male 1 – .34
Female 1.4 0.7–2.9
ICU stay
0–1 1 – .026
$2 3.2 1.1–8.8
Hospital stay
0–5 1 – .20
$6 0.8 0.6–1.1
Pathology






No 1 – .0067
Yes 2.7 1.3–5.6
Hypertension
No 1 – .98
Yes 1.0 0.4–2.2
Diabetes mellitus
No 1 – .49
Yes 1.4 0.5–3.7
Acute myocardial infarction
No 1 – .20
Yes 2.6 0.6–10.9
Congestive heart failure
No 1 – .0068
Yes 3.3 1.4–7.9
Peripheral vascular disease
No 1 – .009
Yes 3.1 1.3–7.5
Preoperative stroke
No 1 – .53
Yes 0.6 0.1–2.7
Obesity
No 1 – .42
Yes 0.4 0.1–3.3
Smoking




No 1 – .0045
Yes 3.2 1.4–7.1
Operating time (min)
,180 1 – .13
$180 2.1 0.8–5.2
TABLE E2. Continued
Hazard ratio 95% CI P value
Procedural urine output
,500 1 – .092
$500 2.1 0.9–5.0
Blood loss (mL)
,400 1 – .039
$400 2.6 1.1–6.5
Contrast use (mL)
,100 1 – .44
$100 1.5 0.5–4.5
Fluoroscopy time (min)
,8 1 – .13
$8 2.1 0.8–5.5
Neck diameter (mm)
,31 1 – .12
$31 2.1 0.8–5.4
Neck length (mm)
,30 1 – .38
$30 0.6 0.2–1.7
General anesthesia
No 1 – .27
Yes 1.6 0.7–3.5
Intraoperative hypotension
No 1 – .23
Yes 2.2 0.6–8.0
Use of adenosine for
cardiac
arrest
No 1 – .48
Yes 0.6 0.2–2.3
Iliac artery conduit
No 0 – .77
Yes 0.9 0.3–2.3
Brachial/radial access
Brachial artery 1 – .78
Radial artery 1.2 0.3–5.2
No. of stent grafts




No 1 – .16
Yes 1.9 0.8–4.6
Landing zone
0–2 1 – .19
3–4 0.6 0.3–1.3
Internal iliac artery coverage
No 1 – .87
Yes 0.8 0.1–6.4
Procedural endoleak
None 1 – .10
Type 1 2.8 0.8–9.8
Endoleak in follow-up
0 1 – .12
1–3 0.4 0.1–1.31109.e3 The Journal of Thoracic and Cardiovascular Surgery c May 2008
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CDTABLE E2. Continued
Hazard ratio 95% CI P value
Postoperative myocardial
infarction
No 1 – ,.001
Yes 8.8 3.6–21.6
Packed red blood units
0 1 – .22
$1 1.7 0.7–4.1
Postoperative bleeding
No 1 – .014
Yes 4.9 1.4–17.6
Infection
No 1 – .29
Yes 1.8 0.6–5.5
Vascular injury
No 1 – .0058
Yes 4.2 1.5–11.8
Distal embolization
No 1 – .16
Yes 2.9 0.7–12.5
Vascular thrombosis
No 1 – .038
Yes 8.8 1.1–68.7
Acute renal failure
No 1 – .023
Yes 3.7 1.2–11.2
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